Aptorum Group Joins the BEAM Alliance To Combat Antimicrobial Resistance
September 08 2020 - 2:00AM
Business Wire
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM)
(“Aptorum Group”), a biopharmaceutical company focused on novel
therapeutics including the development of next-generation
therapeutics targeting antimicrobial resistance, today announced it
joined the Biotech companies in Europe combating Antimicrobial
Resistance Alliance based in Europe (the “BEAM Alliance”) as full
member.
The BEAM Alliance is a network of approximately 70 small and
medium-sized European companies involved in developing innovative
products and kits to tackle antimicrobial resistance (“AMR”),
including small molecule antibiotics, biologics, products with a
prophylaxis indication, microbiome-based and phage-based therapies,
immune targeting therapies, anti-biofilm agents, and medical
devices, including in-vitro diagnostics.
“We are pleased to join the BEAM Alliance and strengthen our
European network with the AMR community. The aims of the alliance
and the pharmaceutical community are particularly synergistic with
one of our core focus in infectious disease research, culminating
the development of our ALS-4 and ALS-2/3 programs, to address
global antimicrobial resistance against deadly bacteria such as
methicillin-resistant staphylococcus aureus (“MRSA”) and others.
Being a part of the BEAM Alliance will further facilitate the
exchange of information and potential establishment of
collaborating partners within this AMR field and we look forward to
contributing our efforts for global preparedness against AMR,” said
Mr. Darren Lui, President and Executive Director of Aptorum
Group.
About Aptorum Group Limited
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a
pharmaceutical company dedicated to the discovery, development and
commercializing of therapeutic assets to treat diseases with unmet
medical needs, particularly infectious diseases and cancers
(including orphan oncology indications). The pipeline of Aptorum is
also enriched through the establishment of drug discovery platforms
that enable the discovery of new therapeutics assets through, e.g.
systematic screening of existing approved drug molecules, and
microbiome-based research platform for treatments of metabolic
diseases. In addition to the above main focus, we are also pursuing
therapeutic and diagnostic projects in neurology, gastroenterology,
metabolic disorders, women’s health and other disease areas. We
also have projects focused on surgical robotics and natural
supplement for women undergoing menopause and experiencing related
symptoms.
For more information about Aptorum Group, please visit
www.aptorumgroup.com.
For further general presentation, please visit:
https://ir.aptorumgroup.com/static-files/ca36cc65-6f23-4105-895e-f5f234ecca1e
About the BEAM Alliance
BEAM represents European biopharmaceutical companies involved in
developing innovative products to tackle antimicrobial resistance.
BEAM collaborates with the existing community of stakeholders
dedicated to implementing tangible strategies. BEAM gives its
members a unique voice to propose and support policies and
incentives in antimicrobial research and development in Europe.
BEAM recommends bold incentives that warrant action by policymakers
to stimulate much-needed innovation.
For more information about BEAM Alliance, please visit
https://beam-alliance.eu/
Disclaimer and Forward-Looking Statements
This press release does not constitute an offer to sell or a
solicitation of offers to buy any securities of Aptorum Group.
This press release includes statements concerning Aptorum Group
Limited and its future expectations, plans and prospects that
constitute “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. For this purpose,
any statements contained herein that are not statements of
historical fact may be deemed to be forward-looking statements. In
some cases, you can identify forward-looking statements by terms
such as “may,” “should,” “expects,” “plans,” “anticipates,”
“could,” “intends,” “target,” “projects,” “contemplates,”
“believes,” “estimates,” “predicts,” “potential,” or “continue,” or
the negative of these terms or other similar expressions. Aptorum
Group has based these forward-looking statements, which include
statements regarding projected timelines for application
submissions and trials, largely on its current expectations and
projections about future events and trends that it believes may
affect its business, financial condition and results of operations.
These forward-looking statements speak only as of the date of this
press release and are subject to a number of risks, uncertainties
and assumptions including, without limitation, risks related to its
announced management and organizational changes, the continued
service and availability of key personnel, its ability to expand
its product assortments by offering additional products for
additional consumer segments, development results, the company’s
anticipated growth strategies, anticipated trends and challenges in
its business, and its expectations regarding, and the stability of,
its supply chain, and the risks more fully described in Aptorum
Group’s Form 20-F and other filings that Aptorum Group may make
with the SEC in the future, as well as the prospectus that received
the French Autorité des Marchés Financiers visa n°20-352 on 16 July
2020.
As a result, the projections included in such forward-looking
statements are subject to change and actual results may differ
materially from those described herein. Aptorum Group assumes no
obligation to update any forward-looking statements contained in
this press release as a result of new information, future events or
otherwise.
This announcement is not a prospectus within the meaning of the
Regulation (EU) n°2017/1129 of 14 June 2017 as amended by
Regulations Delegated (EU) n°2019/980 of 14 March 2019 and
n°2019/979 of 14 March 2019.
This press release is provided “as is” without any
representation or warranty of any kind.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200907005116/en/
Investor relations
Aptorum Group Limited Investor Relations Department: Tel: +44
020 80929299 Email: investor.relations@aptorumgroup.com
Redchip – Financial Communications United States Investor
relations Dave Gentry dave@redchip.com +1 407 491 4498
Actifin – Financial Communications Europe Investor relations
Ghislaine Gasparetto ggasparetto@actifin.fr +33 1 56 88 11 22
Aptorum (NASDAQ:APM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aptorum (NASDAQ:APM)
Historical Stock Chart
From Apr 2023 to Apr 2024